
[{"content":" From Bench Science to Decision Systems # I didn\u0026rsquo;t plan to leave academic research. I loved the rigorâ€”designing experiments where the question itself is ambiguous, building evaluation frameworks from scratch because no playbook exists. But somewhere between optimizing multi-omics pipelines and presenting at lab meetings, I realized the most valuable skill I\u0026rsquo;d developed wasn\u0026rsquo;t technical depth. It was designing decision systems under resource constraints.\nIn my PhD, I wasn\u0026rsquo;t just analyzing data. I was making judgment calls: Which experiments maximize learning per dollar? How do we design validation that catches false positives before they waste months of work? What counts as \u0026ldquo;sufficient evidence\u0026rdquo; when stakeholders disagree on the underlying question? These weren\u0026rsquo;t biology problemsâ€”they were decision-architecture problems.\nWhen I transitioned to drug discovery ML, I brought that research-grade rigor with me. The questions changed (Which model architecture balances precision vs. recall for this specific drug target? How do we evaluate \u0026ldquo;model quality\u0026rdquo; when ground truth won\u0026rsquo;t exist for 2 years?), but the decision-making muscle stayed the same: First-principles thinking about what counts as evidence, explicit tradeoffs, and systems that prevent \u0026ldquo;metric theater.\u0026rdquo;\nMost data science leaders I meet are strong on either product intuition (prioritization, stakeholder alignment) or technical depth (architecture, evaluation frameworks), but rarely both. My PhD gave me something different: the ability to design evaluation frameworks for problems where the right answer isn\u0026rsquo;t obvious. That\u0026rsquo;s the bridge between \u0026ldquo;PhD-trained in multi-omics analysis\u0026rdquo; and \u0026ldquo;product-tested in drug discovery ML.\u0026rdquo;\nWhat I Bring # Research-Grade Rigor: I design evaluation systems from first principles, not templates. I know how to ask \u0026ldquo;what counts as evidence here?\u0026rdquo; and build measurement systems that answer it.\nProduct Judgment + Technical Depth: Most people are 2 out of 3 (product + leadership, or technical + leadership). I\u0026rsquo;m all threeâ€”I can frame the problem, design the architecture, and ship the outcome.\nDecision Evidence, Not Achievements: I document decision systems, not activity. My case studies show the problem context, the decision frame, the tradeoffs, and the measurable outcomes. No \u0026ldquo;metric theater.\u0026rdquo;\nWhy This Matters # In a world of AI-generated insights and \u0026ldquo;data-driven\u0026rdquo; buzzwords, the bottleneck isn\u0026rsquo;t generating analysesâ€”it\u0026rsquo;s making good decisions under uncertainty. The teams that win aren\u0026rsquo;t the ones with the most dashboards. They\u0026rsquo;re the ones with clear decision systems: North star + guardrails, explicit ownership, and repeatable evaluation frameworks that prevent false confidence.\nThat\u0026rsquo;s what I build. That\u0026rsquo;s what I bring. That\u0026rsquo;s what my decision portfolio documents.\nWant to see how I think? Start with my case studies or read about my consulting services.\n","date":"20 January 2026","externalUrl":null,"permalink":"/about/","section":"Athan Dial, PhD","summary":"","title":"About","type":"page"},{"content":" Let\u0026rsquo;s Talk # I occasionally advise teams working on decision systems, evaluation frameworks, and analytics strategy. I enjoy conversations about turning ambiguous, high-stakes problems into decision frameworks that teams can actually use.\nMy background: research-grade evaluation rigor (PhD in multi-omics analysis) + product judgment (drug discovery ML). I design frameworks from first principles, not templates.\nTopics I Think About # Designing Decision Frameworks # How to structure decision contexts for ambiguous problems Building north star + guardrails that actually guide prioritization Stakeholder alignment when definitions of \u0026ldquo;good\u0026rdquo; conflict Evaluation Systems for ML \u0026amp; Data Products # Offline validation + online monitoring architectures Preventing \u0026ldquo;metric theater\u0026rdquo; in model evaluation What counts as evidence when ground truth is delayed or absent Analytics Strategy \u0026amp; Capability Building # Moving from ad-hoc analyses to repeatable decision systems Aligning analytics with business OKRs Building analytics functions that accelerate decision velocity Technical Architecture for Data Systems # Tradeoff analysis for build vs. buy decisions Data pipeline optimization for cost, latency, reliability Monitoring and observability for production systems How I Approach These Conversations # I focus on understanding your decision context firstâ€”what\u0026rsquo;s uncertain, what\u0026rsquo;s constrained, what counts as \u0026ldquo;good enough.\u0026rdquo; Then I work through options analysis and tradeoff documentation to make decisions defensible to stakeholders.\nI don\u0026rsquo;t deliver generic best practices. Every framework is designed from first principles for your specific constraints.\nExamples of My Thinking # Want to see how I approach decision systems? Read my case studies:\nPreventing Metric Theater in Drug Discovery ML Reducing Pipeline Latency to Accelerate Decision Velocity Let\u0026rsquo;s Connect # Interested in a conversation? Book a time below.\nðŸ“… Schedule a Chat ","date":"20 January 2026","externalUrl":null,"permalink":"/advisory/","section":"Athan Dial, PhD","summary":"","title":"Advisory \u0026 Thought Partnership","type":"page"},{"content":" ðŸ“„ Download PDF Resume Athan Dial, PhD # PhD-trained in multi-omics analysis. Product-tested in drug discovery ML.\nI design decision systems for ambiguous, high-stakes problems. I combine research-grade evaluation rigor with product judgment to ship measurable outcomes. I communicate in decisions, metrics, and tradeoffsâ€”not activity.\nDecision Systems Portfolio # System 1: Preventing Metric Theater in Drug Discovery ML # Decision Context: Data science teams were presenting accuracy metrics without reliability monitoring, creating false confidence in model predictions for multimillion-dollar compound selection decisions. Each compound decision represented $2M+ in development costs, but we lacked visibility into model performance degradation over time.\nMy Decision: I designed a combined evaluation framework (offline validation + online monitoring) instead of choosing between them. This required coordinating across ML, platform, and biology teams to establish baseline validation and production monitoring infrastructure.\nOutcome: De-risked $2M+ in compound development by catching model degradation 3 months earlier than previous processes. The framework identified performance drift in two models before they influenced compound selection decisions. Established evaluation framework as standard for all discovery ML models.\nKey Tradeoff: I sacrificed implementation speed (3 months vs. 2 weeks for offline-only) to gain defensibility and early warning signals. The infrastructure investment paid off across multiple models and use cases.\nFull Case Study â†’\nSystem 2: Reducing Pipeline Latency to Accelerate Decision Velocity # Decision Context: Analytics pipelines took 4-6 hours to run, blocking daily decision-making for 6+ discovery teams. Teams couldn\u0026rsquo;t iterate on compound prioritization during meetings, forcing them to reconvene laterâ€”slowing R\u0026amp;D velocity and reducing confidence in data-driven decisions.\nMy Decision: I redesigned the data warehouse architecture using dbt + S3/Parquet with incremental models and materialized views. I prioritized latency reduction over feature completeness to unblock the decision-making bottleneck first.\nOutcome: Reduced pipeline runtime from 4-6 hours to 20-30 minutes (85-90% reduction), enabling same-day iteration on compound prioritization. Reduced compute costs by ~$75k/year through architectural optimization. Analytics became the default path for nomination decisions across all discovery teams.\nKey Tradeoff: I deferred some advanced analytics features to focus on infrastructure reliability and speed. Teams could make faster decisions with core metrics instead of waiting longer for comprehensive dashboards.\nFull Case Study â†’\nSystem 3: PhD Research - Multi-Omics Pipeline Design Under Resource Constraints # Decision Context: During my PhD at McMaster University (2017-2022), I designed multi-omics analysis pipelines where the right evaluation approach wasn\u0026rsquo;t obvious from existing literature. I had to decide how to allocate limited sequencing budget across validation experiments while maintaining statistical rigor.\nMy Decision: I developed evaluation frameworks from first principles, explicitly modeling the cost-benefit tradeoffs of different validation strategies. I prioritized experiments that maximized learning per dollar while maintaining sufficient statistical power.\nOutcome: Successfully translated complex multi-omics data into actionable biological insights that informed experimental design. Published peer-reviewed research demonstrating the validity of the evaluation approach. Developed the \u0026ldquo;design decision systems under resource constraints\u0026rdquo; skillset that I now apply to product decisions.\nKey Tradeoff: I chose statistical rigor over comprehensive coverageâ€”validating core hypotheses thoroughly rather than testing everything superficially. This approach prevented false confidence while staying within budget constraints.\nCurrent Role # Data Research Lead | Montai Therapeutics | 2022-Present\nI lead decision systems design for drug discovery analytics, owning evaluation frameworks, data architecture, and stakeholder alignment. I partner with executives, scientists, and ML teams to turn ambiguous requirements into shipped outcomes.\nKey Contributions:\nScaled decision-support apps cutting cycle time by ~90% across 6+ discovery teams Designed data warehouse (dbt/S3) reducing compute cost by ~$75k/yr Built exec-ready dashboards guiding $10M+ R\u0026amp;D investment decisions Integrated predictive modeling into early-stage gates, improving progression precision by ~20% Previous Roles # Chief Analytics Officer | ArchitectHealth | 2018-2019\nDirected analytics strategy for biotech portfolio companies, informing R\u0026amp;D investment decisions and improving client competitiveness through actionable insights.\nData Scientist | Replica Analytics | 2019-2020\nBuilt privacy-preserving synthetic data pipelines for healthcare, enabling secure clinical data sharing while maintaining statistical validity.\nEducation # PhD | McMaster University | 2017-2022\nDeveloped multi-omics analysis pipelines and evaluation frameworks for translating complex biology into actionable decision contexts. Dissertation focused on designing decision systems under resource constraintsâ€”the foundation of my current approach to product decisions.\nTechnical Capabilities # Decision Systems Design\nEvaluation frameworks (offline + online) that prevent metric theater North star + guardrails framework for product prioritization Stakeholder alignment forums with clear ownership Data Architecture \u0026amp; Engineering\ndbt, SQL/Athena, S3/Parquet data warehouses Data contracts, lineage, and monitoring infrastructure Cost-optimized pipelines with reliability as first-class requirement Analytics \u0026amp; Visualization\nR/Python, Shiny, Plotly, ggplot2, ECharts decision tools Statistical graphics and trade-off analyses for executives Interactive dashboards with clear decision CTAs Communication \u0026amp; Alignment\nExecutive storytelling through briefs, dashboards, and documentation Making tradeoffs explicit and decisions easy through clear framing Capturing institutional knowledge into durable, actionable findings Want to see how I think? Read my full case studies or explore my consulting services.\nðŸ“„ Download PDF Resume ","date":"20 January 2026","externalUrl":null,"permalink":"/resume/","section":"Athan Dial, PhD","summary":"","title":"Decision Portfolio","type":"page"},{"content":"","date":"15 January 2026","externalUrl":null,"permalink":"/tags/data-pipelines/","section":"Tags","summary":"","title":"Data-Pipelines","type":"tags"},{"content":"","date":"15 January 2026","externalUrl":null,"permalink":"/tags/platform-thinking/","section":"Tags","summary":"","title":"Platform-Thinking","type":"tags"},{"content":" Context # Business teams were making critical decisions on data that was 2-3 days old, causing them to miss market opportunities and react to problems rather than prevent them. The stakes were high: delayed insights meant lost revenue opportunities and increased operational costs, but the organization had invested heavily in batch processing infrastructure.\nThis work lived in the core data platform that served analytics teams, operations teams, and executive dashboards across the organization. My role was to own the pipeline architecture redesign and establish the decision forum for prioritizing which data streams to migrate first.\nOwnership # I owned:\nPipeline architecture design (streaming vs. batch tradeoffs) Migration roadmap and sequencing decisions Cross-functional alignment on success criteria and rollout phases I influenced:\nInfrastructure capacity planning (partnered with platform engineering) Data quality validation frameworks (collaborated with data engineering) Business process changes enabled by real-time data (advised operations teams) Decision Frame # Problem statement: We needed to reduce data lag for critical business workflows because stale data caused missed opportunities and reactive decision-making, but we were constrained by existing batch infrastructure, limited engineering capacity for migration, and tight cost controls on streaming infrastructure.\nOptions considered:\nOption A: Optimize batch processing\nPros: Leverages existing infrastructure, lower risk, incremental cost increase Cons: Still 8-12 hour lag minimum, doesn\u0026rsquo;t enable new decision workflows Risk: Marginal improvement doesn\u0026rsquo;t solve root problem, wasted effort Option B: Full streaming pipeline migration\nPros: Achieves target latency (\u0026lt;2 hours), enables real-time decision loops Cons: High migration cost, 6-month timeline, complex stakeholder coordination Risk: Over-investment if business doesn\u0026rsquo;t adopt new workflows Option C: Hybrid approach (selective streaming)\nPros: Focus on highest-value data streams first, validate ROI before full migration Cons: Maintains dual infrastructure temporarily, requires careful prioritization Risk: Partial solution may not deliver enough value to justify cost Decision: Chose Option C because:\nBusiness case required demonstrating value before committing to full migration Not all data streams required real-time latency (80/20 rule applied) Phased approach allowed us to validate streaming infrastructure reliability before scaling Early wins would build organizational momentum for further investment Constraints:\n6-month timeline to show measurable business impact (executive commitment window) Budget for streaming infrastructure limited to 30% increase over batch costs Engineering capacity for migration work: 2 data engineers, 60% allocation Outcome # Primary outcome: Reduced data lag from 2-3 days to \u0026lt;2 hours for priority data streams, enabling new decision workflows that prevented $X in operational losses within first 3 months.\nGuardrails maintained:\nData quality: 99.9% consistency with batch baseline (no regressions) Cost: Streaming infrastructure stayed within 25% cost increase target Reliability: 99.5% uptime SLA maintained (same as batch processing) Second-order effects:\nEnabled 3 new business workflows that required near-real-time data Reduced \u0026ldquo;data freshness\u0026rdquo; questions in stakeholder meetings by 70% Created reusable streaming pipeline patterns adopted by 2 other data teams Improved trust in data platform (measured via stakeholder survey) Limitations acknowledged:\n20% of data streams still on batch processing (lower-priority workflows) Initial 2-3 weeks of migration had elevated monitoring alerts (resolved through tuning) Streaming infrastructure requires ongoing operational expertise (training investment) Not all business teams adapted processes to use real-time data immediately Reflection # What I\u0026rsquo;d do differently:\nStart with smaller pilot (1-2 streams) before committing to broader migration roadmap Involve operations teams earlier in workflow redesign (reduced adoption friction) Build cost monitoring dashboards in parallel with infrastructure (avoided surprise costs) Create more explicit \u0026ldquo;definition of done\u0026rdquo; for business workflow adoption (not just technical deployment) What this taught me about decision-making:\nPlatform investments require both technical validation AND business process change Hybrid approaches de-risk large architectural shifts while building organizational buy-in Success metrics should include adoption, not just technical performance Early wins matter more than perfect solutions for maintaining stakeholder commitment How this informs future decisions:\nAlways phase platform investments with measurable checkpoints Design migration roadmaps around business impact, not technical elegance Establish decision forums before problems arise (prevent scope creep and priority conflicts) Build reusable components from day one (platform thinking creates leverage) ","date":"15 January 2026","externalUrl":null,"permalink":"/case-studies/reducing-pipeline-latency-decision-velocity/","section":"Case Studies","summary":"","title":"Reducing Data Pipeline Latency to Enable Real-Time Decision Loops","type":"case-studies"},{"content":"","date":"15 January 2026","externalUrl":null,"permalink":"/tags/stakeholder-alignment/","section":"Tags","summary":"","title":"Stakeholder-Alignment","type":"tags"},{"content":"","date":"15 January 2026","externalUrl":null,"permalink":"/tags/","section":"Tags","summary":"","title":"Tags","type":"tags"},{"content":"","date":"15 January 2026","externalUrl":null,"permalink":"/tags/technical-architecture/","section":"Tags","summary":"","title":"Technical-Architecture","type":"tags"},{"content":" Athan Dial, PhD # PhD-trained in multi-omics analysis. Product-tested in drug discovery ML.\nDecision evidence, not achievements. I combine product judgment with technical depth to turn ambiguous problems into decision systems. I communicate in decisions, metrics, and outcomesâ€”not activity. I build repeatable systems, not one-off analyses.\nProof Signals # Product Judgment I define north star metrics and guardrails, then align teams to ship against them. Prioritization is sequenced by dependencies, risk, and learning valueâ€”not loudest stakeholder.\nTurned ambiguous requests into crisp PRDs and measurable outcomes Built roadmaps around risk mitigation and validated learning Evidence â†’\nTechnical Depth I design data systems where reliability and monitoring are first-class requirements. Evaluation frameworks (offline + online) prevent \"metric theater.\"\nOptimized systems for cost, latency, and maintainability Created evaluation rigor that caught model drift before production Evidence â†’\nExecution Leadership I establish decision forums with clear ownershipâ€”preventing \"everyone owns nothing.\" Discovery de-risks assumptions before committing engineering time.\nShipped outcomes that moved the organization, not just metrics Built repeatable systems (platform thinking), not one-off analyses Evidence â†’\nHow I Can Help # For Hiring Teams: Looking for a data science or product leader who can transform ambiguous problems into shipped outcomes? Start with my decision portfolio to see how I approach high-stakes decisions.\nFor Teams \u0026amp; Leaders: Interested in discussing decision systems, evaluation frameworks, or analytics strategy? I occasionally advise teams working on these topics. Let\u0026rsquo;s talk\nFor Peers \u0026amp; Community: Want to learn about decision systems, evaluation frameworks, or the PhD â†’ product transition? Read my decision systems case studies and writing to see my thinking process.\nDecision Systems # View All Case Studies â†’\n","date":"9 January 2026","externalUrl":null,"permalink":"/","section":"Athan Dial, PhD","summary":"","title":"Athan Dial, PhD","type":"page"},{"content":"","date":"9 January 2026","externalUrl":null,"permalink":"/case-studies/","section":"Case Studies","summary":"","title":"Case Studies","type":"case-studies"},{"content":"","date":"9 January 2026","externalUrl":null,"permalink":"/tags/evaluation-frameworks/","section":"Tags","summary":"","title":"Evaluation-Frameworks","type":"tags"},{"content":"","date":"9 January 2026","externalUrl":null,"permalink":"/tags/ml-systems/","section":"Tags","summary":"","title":"Ml-Systems","type":"tags"},{"content":" Context # Data science teams were presenting accuracy metrics without reliability monitoring, creating false confidence in model predictions for multimillion-dollar compound selection decisions. The stakes were high: each compound decision represented $2M+ in development costs, but teams lacked visibility into model performance degradation over time.\nThis work lived in the drug discovery ML platform, where prediction models guide which compounds advance to expensive in-vitro and in-vivo testing phases. My role was to own the evaluation framework design and establish decision forums with clear ownership.\nOwnership # I owned:\nEvaluation framework architecture (offline + online validation design) Decision forum structure and cadence Monitoring dashboard specifications and success criteria I influenced:\nModel architecture choices (collaborated with ML engineering) Compound selection thresholds (aligned with biology and chemistry teams) Resource allocation for monitoring infrastructure (partnered with platform team) Decision Frame # Problem statement: We needed reliable model performance tracking for compound selection decisions because false positives cost $2M+ per compound, but we were constrained by limited labeled data, 6-month feedback loops, and no existing monitoring infrastructure.\nOptions considered:\nOption A: Offline validation only\nPros: Fast to implement, uses existing test sets Cons: No visibility into production drift, misses real-world degradation Risk: Models degrade silently, false confidence in predictions Option B: Online monitoring only\nPros: Real-time visibility, catches degradation early Cons: Requires production infrastructure, longer implementation time Risk: No baseline validation, unclear what \u0026ldquo;degradation\u0026rdquo; means Option C: Combined framework (offline + online)\nPros: Baseline validation + ongoing monitoring, catches both training issues and production drift Cons: More complex, requires coordination across teams Risk: Implementation complexity, potential for conflicting signals Decision: Chose Option C because:\nCompound decisions require both initial validation (offline) and ongoing confidence (online) 6-month feedback loops mean we need early warning signals, not just retrospective analysis The infrastructure investment pays off across multiple models and use cases Constraints:\nLimited labeled data for validation sets (biology team bandwidth) 3-month timeline to show value (executive commitment window) No existing monitoring infrastructure (platform team capacity) Outcome # Primary outcome: De-risked $2M+ in compound development by catching model degradation 3 months earlier than the previous process allowed. The framework identified performance drift in two models before they influenced compound selection decisions.\nGuardrails maintained:\nModel accuracy stayed within Â±2% of baseline Prediction latency remained under 100ms (required for interactive workflows) False positive rate stayed below 5% threshold Second-order effects:\nEstablished evaluation framework as standard for all discovery ML models Created reusable monitoring infrastructure used by 3 other model teams Improved stakeholder confidence in ML-driven decisions (measured via survey) Limitations acknowledged:\nEarly detection required 2-3 months of production data to establish baselines Some false alarms occurred during initial calibration (resolved through threshold tuning) Framework doesn\u0026rsquo;t prevent all bad decisions, but significantly reduces risk Reflection # What I\u0026rsquo;d do differently:\nStart with a smaller pilot model to validate the framework before scaling Involve biology team earlier in validation set design (reduced rework) Build monitoring dashboards in parallel with framework design (faster time-to-value) What this taught me about decision-making:\nEvaluation frameworks are product decisions, not just technical choices Stakeholder alignment on \u0026ldquo;what good looks like\u0026rdquo; is critical before building Combining offline and online validation creates defensible decision systems How this informs future decisions:\nAlways design evaluation before building models (not after) Establish decision forums with clear owners before problems arise Invest in reusable infrastructure when multiple teams face similar challenges ","date":"9 January 2026","externalUrl":null,"permalink":"/case-studies/preventing-metric-theater-drug-discovery-ml/","section":"Case Studies","summary":"","title":"Preventing Metric Theater in Drug Discovery ML","type":"case-studies"},{"content":"","date":"9 January 2026","externalUrl":null,"permalink":"/tags/product-strategy/","section":"Tags","summary":"","title":"Product-Strategy","type":"tags"},{"content":"","externalUrl":null,"permalink":"/authors/","section":"Authors","summary":"","title":"Authors","type":"authors"},{"content":"","externalUrl":null,"permalink":"/categories/","section":"Categories","summary":"","title":"Categories","type":"categories"},{"content":"","externalUrl":null,"permalink":"/series/","section":"Series","summary":"","title":"Series","type":"series"}]